miR-584-5p is a New Potential Prognostic Biomarker in Head and Neck Squamous Cell Carcinoma

Background: MicroRNA-584-5p (miR-584-5p) plays an important role in certain types of cancer. However its precise role in head and neck squamous cell carcinoma (HNSC) remains unknown. Objective: Our aim was to investigate how miR-584-5p influences HNSC. Methods: The Cancer Genome Atlas (TCGA) provided samples for the study. We use statistical methods to evaluate the diagnostic value the prognostic value and the correlation with the clinical features of miR-584-5p. We analyze the target genes and the regulatory network of miR-584-5p. Quantitative reverse transcriptase PCR (qRT-PCR) confirmed the expression of miR-584-5p in HNSC cell lines. Results: MiR-584-5p expression of miR-584-5p varied significantly among different types of cancer. A notable correlation was observed between elevated miR-584-5p expression and gender (p < 0.001) and histological grade (p < 0.001). Furthermore, high levels of miR-584-5p were found to be associated with a decrease in overall survival (HR: 1.44 95% CI: 1.10-1.88 p = 0.007), progression-free survival (HR: 1.35 95% CI: 1.02-1.79 p = 0.035) and disease-specific survival (HR: 1.54 95% CI: 1.09-2.18 p = 0.016) in the context of HNSC. miR-584-5p demonstrated independent prognostic significance in HNSC and potentially contributes to disease progression through multiple pathways, such as dilated cardiomyopathy and hypertrophic cardiomyopathy. In particular, HNSC cell lines exhibited a substantial upregulation of miR-584-5p compared to normal epithelial cells Conclusions: It is possible that miR-584-5p could serve as a promising patent for a therapeutic target and prognostic biomarker for people with HNSC.